武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

TAK 武田制药

盘后交易 04-30 19:21:57 EDT

16.68

+0.38

+2.33%

盘后16.68

+0.000.00%

16:10 EDT

最高16.77	最低16.64	成交量210.09万
今开16.70	昨收16.30	日振幅0.80%
总市值526.95亿	流通市值509.91亿	总股本31.59亿
成交额3,511万	换手率0.07%	流通股本30.57亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"TAK","market":"US","secType":"STK","nameCN":"武田制药","latestPrice":16.68,"timestamp":1777579200000,"preClose":16.3,"halted":0,"volume":2100911,"hourTrading":{"tag":"盘后","latestPrice":16.68,"preClose":16.68,"latestTime":"16:10 EDT","volume":4708,"amount":78529.44,"timestamp":1777579804165,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.02331288343558276,"floatShares":3057000000,"shares":3159188548,"eps":0.224727,"marketStatus":"盘后交易","change":0.38,"latestTime":"04-30 19:21:57 EDT","open":16.7,"high":16.77,"low":16.64,"amount":35107041.550136,"amplitude":0.007975,"askPrice":17.75,"askSize":2,"bidPrice":15,"bidSize":1,"shortable":3,"etf":0,"ttmEps":0.224727,"tradingStatus":3,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777593600000},"marketStatusCode":4,"adr":0,"adrRate":0.5,"listingDate":1545627600000,"exchange":"NYSE","adjPreClose":16.3,"dividendRate":0.037167,"preHourTrading":{"tag":"盘前","latestPrice":16.67,"preClose":16.3,"latestTime":"08:23 EDT","volume":2208,"amount":36693.996864,"timestamp":1777551803080,"change":0.37,"changeRate":0.022699,"amplitude":0.016564},"postHourTrading":{"tag":"盘后","latestPrice":16.68,"preClose":16.68,"latestTime":"16:10 EDT","volume":4708,"amount":78529.44,"timestamp":1777579804165,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.029809,"impliedVol":0.3777,"impliedVolPercentile":0.7052},"requestUrl":"/m/hq/s/TAK","defaultTab":"news","newsList":[{"id":"2622785300","title":"武田制药(TAK.US)拟计提1500亿日元重组费用，以AI驱动降本增效","url":"https://stock-news.laohu8.com/highlight/detail?id=2622785300","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2622785300?lang=zh_cn&edition=full","pubTime":"2026-03-25 19:31","pubTimestamp":1774438281,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，日本制药巨头武田制药计划在即将于下月开启的新财年中计提约1500亿日元的重组费用。武田制药的重组是大型制药企业拥抱人工智能这一更广泛趋势的一部分，因为不断上涨的研发成本挤压了利润空间，加剧了市场竞争。据了解，武田制药目前已与其合作伙伴及内部AI团队在银屑病等多个管线中取得初步进展，这被市场视为其从传统药企向技术驱动型生物医药公司转型的信号。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418910.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AGIX","CHAT","BK4007","TAK","AIPO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617959547","title":"诺和诺德、武田、默克等齐换帅，中国市场进入战略新周期","url":"https://stock-news.laohu8.com/highlight/detail?id=2617959547","media":"动脉网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617959547?lang=zh_cn&edition=full","pubTime":"2026-03-05 09:53","pubTimestamp":1772675580,"startTime":"0","endTime":"0","summary":"2026年以来，诺和诺德、武田、默克等多家跨国药企相继完成中国区“换帅”。费森尤斯卡比中国宣布张巍3月2日加入，4月3日起任总裁兼董事长，她拥有超二十年医药行业经验；罗杰仁2月1日起任默克中国总裁，1月1日起兼任默克生命科学中国负责人，在医药健康和生命科学领域经验丰富；穆安德2月1日起任默克中国医药健康业务董事总经理，他是内部提拔晋升而来；诺和诺德中国宣布周霞萍3月31日离任，蔡琰同日接任大中国区总裁，周霞萍助力公司10款新药获批上市，蔡琰是资深管理者；1月底武田制药任命刘燕为武田中国总裁，负责整体战略和业务发展。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260305100816a6a46605&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU2125154778.USD","BK4534","SG9999014559.SGD","SG9999002224.SGD","ASHS","MCHI","BK4504","LU0477156953.USD","TAK","NVOX","BK4007","LU2106854487.HKD","LU1162221912.USD","BK4588","LU0320765489.SGD","SG9999014567.USD","LU1941712348.USD","LU2125154935.USD","LU1069347547.HKD","LU1983299246.USD","LU0965509010.AUD","LU1430594728.SGD","LU1061106388.HKD","LU1291159041.SGD","LU0130517989.USD","LU0266013472.USD","LU1023059063.AUD","LU1035773651.USD","LU1066051225.USD","LU1934455194.USD","CWEB","IE00B1BXHZ80.USD","LU0432979614.USD","LU0289739699.SGD","LU0130102774.USD","BK4550","LU1929549753.HKD","LU0942090050.USD","LU0203345920.USD","LU1917777945.USD","LU1699723380.USD","IE00B4R5TH58.HKD","BK4599","MRK","IE00B2B36J28.USD","LU0006306889.USD","SG9999002232.USD","IE000M9KFDE8.USD","SGXZ57979304.SGD","LU2112291526.USD","SG9999014575.USD","LU1066051498.USD","ASHR","LU1974910355.USD","LU2089984988.USD","LU0234572021.USD","LU0238689110.USD","BK4614","LU2361045086.USD","SG9999013999.USD","IE00BSNM7G36.USD","LU2361044949.HKD","LU0265550946.USD","LU0965509101.SGD","LU2023250504.SGD","LU1585245621.USD","LU1037948541.HKD","SG9999015358.SGD","LU0203347892.USD","LU0208291251.USD","IE00BLSP4452.SGD","IE0009355771.USD","BK4532","NVOH","SG9999001176.USD","LU0154236417.USD","IE00BLSP4239.USD","IE00BFTCPJ56.SGD","LU0965508806.USD","LU0098860793.USD","LU1941712264.USD","KWEB","LU1989771016.USD","LU0980610538.SGD","IE00BJT1NW94.SGD","LU2360032135.SGD","LU2461242641.AUD","BK4585","LU1037948897.HKD","LU1066051811.HKD","IE00BBT3K403.USD","LU1201861249.SGD","IE00BZ1G4Q59.USD","LU2023250843.SGD","SG9999014542.SGD","IE00BKVL7J92.USD","LU1989772840.SGD","LU1093756168.USD","LU0265550359.USD","BK4533","LU1116320737.USD","CQQQ","LU1116320901.HKD","LU1571399168.USD","LU1934455277.USD","SG9999001440.SGD","LU1057294990.SGD","LU1066053197.SGD","IE00BN8TJ469.HKD","LU0965509283.SGD","LU0985320562.USD","BK4559","LU2324357040.USD","LU0122379950.USD","LU0070302665.USD","SG9999001176.SGD","LU0058720904.USD","LU0868494617.USD","LU0861579265.USD","LU1934455863.HKD","LU0211331839.USD","LU0106261372.USD","LU1989772923.USD","LU0868494708.USD","LU2361044865.SGD","LU2468319806.SGD","LU0320765646.SGD","DRAG","IE00BJJMRZ35.SGD","NVO","SG9999015341.SGD","LU0648001328.SGD","LU0963586101.USD","IE0002141913.USD","BK4516","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610653473","title":"武田制药以17亿美元收购Iambic 加码人工智能药物研发布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2610653473","media":"环球市场播报","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610653473?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:26","pubTimestamp":1770643560,"startTime":"0","endTime":"0","summary":"私人控股企业Iambic于本周一宣布，已与日本武田制药达成价值超17亿美元的多年期合作，双方将借助人工智能技术，助力研发针对癌症和胃肠道疾病的小分子药物。　　根据协议内容，Iambic将获得首付款，同时还可在药物研发及商业化的各里程碑节点获得超17亿美元的相关款项，此外还能享有药品销售的特许权使用费。　　这笔合作是武田制药继去年与Nabla Bio达成聚焦蛋白类药物的同类合作后，在研发全流程布局人工智能技术的又一重要举措。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-02-09/doc-inhmfuky5165106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4007","161631","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607061263","title":"武田制药任命刘燕为武田中国总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2607061263","media":"南方财经网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607061263?lang=zh_cn&edition=full","pubTime":"2026-01-30 10:56","pubTimestamp":1769741778,"startTime":"0","endTime":"0","summary":"南方财经1月30日电，据“武田中国”微信公众号消息，日前，武田制药宣布任命刘燕为武田中国总裁，全面负责武田中国（包括香港、澳门地区）的整体战略和业务发展。她也同时成为新成立的武田制药国际事业部管理委员会成员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202601303636687966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605842904","title":"武田(TAK.US)1类新药奥博雷通片拟纳入优先审评 适用于1型发作性睡病患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2605842904","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605842904?lang=zh_cn&edition=full","pubTime":"2026-01-23 14:43","pubTimestamp":1769150602,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，中国国家药监局药品审评中心官网近日公示显示，武田申报的1类新药奥博雷通片的上市申请拟纳入优先审评，适用于治疗16岁及以上1型发作性睡病患者。发作性睡病I型是一种罕见的慢性中枢神经系统疾病，由于患者的食欲素神经元大量缺失，导致大脑和脑脊液中食欲素神经肽水平低下。2025年7月，武田宣布奥博雷通片的两项针对NT1的3期研究达到所有主要和次要终点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396593.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1158037503","title":"财报前瞻｜武田制药本季度营收预计小幅增长，机构观点偏谨慎","url":"https://stock-news.laohu8.com/highlight/detail?id=1158037503","media":"财报Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1158037503?lang=zh_cn&edition=full","pubTime":"2026-01-22 10:22","pubTimestamp":1769048526,"startTime":"0","endTime":"0","summary":"武田制药将于2026年01月29日发布最新季度财报，市场聚焦营收改善与利润恢复节奏，关注核心管线商业化对利润率的影响。市场一致预期本季度武田制药总收入约为1149.65亿美元，同比增长6.05%，预计EBIT为105.89亿美元，同比增长174.79%；公司上个季度财报口径显示对本季度的收入与利润预期以改善为主，但净利润和每股收益的预测未披露，毛利率与净利率的季度预测数据暂无。近期机构对武田制药的观点偏谨慎，看空比例更高。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"财报前瞻｜武田制药本季度营收预计小幅增长，机构观点偏谨慎","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603683739","title":"武田制药(TAK.US)1类新药“奥博雷通片”在中国申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2603683739","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603683739?lang=zh_cn&edition=full","pubTime":"2026-01-16 15:32","pubTimestamp":1768548757,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月16日，中国国家药监局药品审评中心官网最新公示显示，武田制药申报的1类新药奥博雷通片上市申请获得受理。该产品此前已经被CDE纳入突破性治疗品种，针对1型发作性睡病适应症。其针对NT1适应症的两项3期关键性研究已经达到所有主要和次要终点。在刚刚结束的2026年JPM大会上，武田披露该产品预计于2026年下半年获监管机构批准上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1393785.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"武田制药(TAK.US)1类新药“奥博雷通片”在中国申报上市","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2593637123","title":"产业新闻丨武田公布TYK2抑制剂治疗银屑病3期临床研究积极结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2593637123","media":"医药观澜","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593637123?lang=zh_cn&edition=full","pubTime":"2025-12-20 12:12","pubTimestamp":1766203940,"startTime":"0","endTime":"0","summary":"武田制药计划在即将举行的医学会议上公布研究数据，并计划自2026财年向美国FDA及其他监管机构递交新药上市申请。Zasocitinib是一款在研的新一代高选择性口服TYK2抑制剂，可在24小时内持续抑制IL-23以及其他驱动疾病进展的核心免疫通路。武田目前正开展Zasocitinib与在斑块状银屑病中的研究，并推进其在银屑病关节炎中的3期临床试验。Zasocitinib目前仍处于研究阶段，尚未获得任何监管机构的上市批准。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220121640a46276e2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251220121640a46276e2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2592180118","title":"产业新闻 | 诺和诺德向FDA递交CagriSema上市申请；武田下一代小分子疗法达两项3期试验双主要终点……","url":"https://stock-news.laohu8.com/highlight/detail?id=2592180118","media":"药明康德","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592180118?lang=zh_cn&edition=full","pubTime":"2025-12-19 07:32","pubTimestamp":1766100744,"startTime":"0","endTime":"0","summary":"诺和诺德向FDA递交CagriSema上市申请诺和诺德今日宣布，已向美国FDA递交CagriSema的新药申请。根据新闻稿，若获批，CagriSema将成为首个可注射GLP-1受体激动剂+胰淀素类似物的联合治疗方案。而在假设所有患者均持续用药的前提下，CagriSema组在第68周的体重下降幅度为22.7%，安慰剂组为2.3%。此外，CagriSema组有91.9%的受试者体重下降幅度达到或超过5%，而安慰剂组为31.5%。两项试验均为随机、多中心、双盲设计，并设置安慰剂及活性药物对照。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219073557a6b454f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219073557a6b454f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4588","LU0154236417.USD","BK4599","IE00BZ1G4Q59.USD","TAK","NVO","IE00BKVL7J92.USD","BK4007","LU1093756168.USD","BK4532","BK4585","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2592909774","title":"武田制药公布银屑病新药临床研究结果 每日一次口服方案有望实现皮损清除","url":"https://stock-news.laohu8.com/highlight/detail?id=2592909774","media":"中国网财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592909774?lang=zh_cn&edition=full","pubTime":"2025-12-18 21:31","pubTimestamp":1766064673,"startTime":"0","endTime":"0","summary":"中国网财经12月18日讯武田制药今日宣布，其针对中重度斑块状银屑病(PsO)成人患者的新一代、高选择性口服酪氨酸激酶2(TYK2)抑制剂Zasocitinib(TAK-279)在两项关键性3期、随机、多中心、双盲、安慰剂与活性对照研究中取得积极的主要结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512183595727826.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512183595727826.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4007","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2589685310","title":"信达生物(01801)完成与武田制药的全球战略合作及根据一般授权发行691.38万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2589685310","media":"智通财经","labels":["shareholding","corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589685310?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:15","pubTimestamp":1764890112,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，内容有关信达生物与武田制药达成全球战略合作，许可、选择权及合作协议及股份发行协议各自的所有先决条件均已达成或获豁免(如适用)。于股份发行协议完成后，公司向认购人配发及发行691.38万股股份，占发行认购股份后公司已发行股本的约0.40%。配发及发行认购股份的所得款项总额约为7.78亿港元，而所得款项净额约为7.77亿港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377949.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","LU2328871848.SGD","LU2097828557.USD","LU2097828805.USD","BK1589","LU2097828474.EUR","LU0455707207.USD","LU2242644610.SGD","TAK","LU2097828714.EUR","LU0502904849.HKD","01801","BK1161","LU1969619763.USD","BK4007","LU2097828631.EUR","HK0000165453.HKD","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2584786920","title":"Neurocrine公司抑郁症新药II期研究未达主要终点","url":"https://stock-news.laohu8.com/highlight/detail?id=2584786920","media":"GPLP犀牛财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2584786920?lang=zh_cn&edition=full","pubTime":"2025-11-19 19:34","pubTimestamp":1763552095,"startTime":"0","endTime":"0","summary":"近日，神经科学领域的生物制药公司Neurocrine Biosciences宣布，在研抑郁症药物NBI-1070770的II期临床试验未能达到预设主要终点，这一结果也为其与武田制药的合作研发项目再添波折。该药物的研发权益源于2020年Neurocrine与武田的合作，当时武田授予其七个在研药物的独家许可，NBI-1070770便是其中针对抑郁症的核心资产之一。Neurocrine在声明中指出，NBI-1070770整体耐受性良好，试验期间未报告严重不良事件，但所有剂量组均未在主要终点上展现出优于安慰剂的统计学差异。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251119193517950e580f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4007","TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2581285230","title":"医药行业 “砍单潮” 来袭，研发管线迎大调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2581285230","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2581285230?lang=zh_cn&edition=full","pubTime":"2025-11-08 16:27","pubTimestamp":1762590458,"startTime":"0","endTime":"0","summary":"11月医药行业 “砍单潮” 打破了研发领域的平静。此次终止的项目中，“数据未达预期” 成为高频原因，暴露出前沿疗法的研发痛点。阿斯利康的 MASH 药物 AZD2693 则在 2b 期试验中因 “疗效不佳” 被叫停，成为该领域研发折戟的又一案例。阿斯利康的调整同样遵循 “优先级法则”，终止 KRAS G12D 抑制剂 AZD0022 等项目，正是为了聚焦自主研发的下一代 ADC 等核心管线。辉瑞仍保有 101 个在研项目，阿斯利康在 ADC 领域的自主研发持续加码。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108162941a6eaa43d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108162941a6eaa43d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["NVO","LU1057294990.SGD","BK4599","SG9999001176.SGD","LU0234572021.USD","PFE","SG9999001176.USD","LU0170899867.USD","LU0122379950.USD","LU1883839398.USD","LU1894683264.USD","IE00BLSP4239.USD","LU0868494617.USD","IE00BKVL7J92.USD","SG9999002232.USD","BK4588","LU0456855351.SGD","BK4532","IE000M9KFDE8.USD","LU0321505439.SGD","LU0985481810.HKD","BK4568","LU1093756325.SGD","LU0289739699.SGD","LU0225771236.USD","LU0225284248.USD","SGXZ57979304.SGD","LU1894683348.USD","TAK","BK4534","IE00B19Z3B42.SGD","IE00B19Z3581.USD","IE00BZ1G4Q59.USD","SG9999002224.SGD","BK4581","LU0306806265.USD","BK4007","LU0321505868.SGD","BK4533","IE00BLSP4452.SGD","BK4592","BK4550","SG9999011175.SGD","LU1066051498.USD","BK4585","SG9999013999.USD","LU1093756168.USD","IE00BBT3K403.USD","LU1023059063.AUD","IE0002270589.USD","LU0154236417.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2580746447","title":"三巨头同日终止6项临床项目！","url":"https://stock-news.laohu8.com/highlight/detail?id=2580746447","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580746447?lang=zh_cn&edition=full","pubTime":"2025-10-31 21:01","pubTimestamp":1761915689,"startTime":"0","endTime":"0","summary":"百时美施贵宝 、 礼来 、武田三大跨国药企同步宣布终止6项临床阶段项目，覆盖肿瘤、慢性疼痛、神经疾病等热门治疗领域。BMS此次调整涉及两项关键战略资产，均与此前大额投资布局相关。不过礼来强调与旭化成的licensing 协议仍有效，目前正评估该药物用于其他适应症的可能性。值得注意的是，P2X7靶点此前已多次折戟，GSK、 阿斯利康 等企业均曾因数据或疗效问题终止相关项目。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031211741a4801ac9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251031211741a4801ac9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1923622291.USD","LU2211815571.USD","LU0728928796.USD","LU0757428866.USD","BK4143","LU1815336091.USD","LU2125909759.SGD","LU2125909916.SGD","MSA","TAK","LU0053671581.USD","BMS","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2509264672","title":"日本制药股走高，中外制药涨超4%，盐野义制药涨超3%，武田制药、日本新药涨超1%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2509264672","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2509264672?lang=zh_cn&edition=full","pubTime":"2025-02-06 08:57","pubTimestamp":1738803431,"startTime":"0","endTime":"0","summary":"日本制药股走高，中外制药涨超4%，盐野义制药涨超3%，武田制药、日本新药涨超1%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/06085747977826.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TAK","BK1574","BK4007","BK1191","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507629998","title":"Julie Kim将于明年接替卫博科出任武田制药总裁兼CEO","url":"https://stock-news.laohu8.com/highlight/detail?id=2507629998","media":"港股那点事","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507629998?lang=zh_cn&edition=full","pubTime":"2025-01-30 21:58","pubTimestamp":1738245480,"startTime":"0","endTime":"0","summary":"格隆汇1月30日｜武田制药宣布，董事会一致决定由公司美国业务部总裁Julie Kim接替卫博科（Christophe Weber）出任公司总裁、CEO兼代表董事，2026年6月生效，后者届时将退休。               \n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/bxjj/2025-01-30/doc-inehunpu2484439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BRCD","TAK","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2507669648","title":"Takeda Pharmaceutical(TAK.US)：2024年Q3财报实现营收75.13亿美元，前值为78.85亿美元；每股收益为0.44美元，前值为0.51美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2507669648","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2507669648?lang=zh_cn&edition=full","pubTime":"2025-01-30 17:24","pubTimestamp":1738229099,"startTime":"0","endTime":"0","summary":"Takeda Pharmaceutical(TAK.US)：2024年Q3财报实现营收75.13亿美元，前值为78.85亿美元；每股收益为0.44美元，前值为0.51美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/30172447906893.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188918826","title":"武田药品提高2024财年指导预期：核心收入和利润预期小幅增长，核心每股收益调整为持平或略有下降，自由现金流提高至5500亿至6500亿日元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188918826","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188918826?lang=zh_cn&edition=full","pubTime":"2025-01-30 15:30","pubTimestamp":1738222214,"startTime":"0","endTime":"0","summary":"武田药品更新了其2024财年的管理指导和报告及核心预测。这些调整主要受产品动能和运营费用节约的推动，同时也反映了修订后的全年汇率假设。根据最新的预测，核心收入预计将小幅增长，而核心每股收益预计与之前持平或略微下降。此外，自由现金流的预期被上调至5500亿至6500亿日元。查看更多详情，请参考《2024财年财务预测修订公告》。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1118495484","title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","url":"https://stock-news.laohu8.com/highlight/detail?id=1118495484","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1118495484?lang=zh_cn&edition=full","pubTime":"2025-01-30 14:56","pubTimestamp":1738220174,"startTime":"0","endTime":"0","summary":"武田药品  报告季度每股收益为15.01日元。这较去年同期的每股收益67.38日元下降了77.72%。公司报告季度销售额为1.144万亿日元，超出分析师一致预期的1.139万亿日元，超出0.42%。以上内容来自Benzinga Earnings专栏，原文如下：Takeda Pharmaceutical  reported quarterly earnings of 15.01 per share. This is a 77.72 percent decrease over earnings of 67.38 per share from the same period last year. The company reported quarterly sales of 1.144 trillion which beat the analyst consensus estimate of 1.139 trillion by 0.42 percent. This is a 2.97 percent increase over sales of 1.111 trillion the same","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"武田药品2024年第三季度GAAP每股收益为15.01日元，同比下降67.38日元，销售额为1.144万亿日元，超出预期1.139万亿日元","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TAK"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.takeda.com","stockEarnings":[{"period":"1week","weight":-0.0181},{"period":"1month","weight":-0.1078},{"period":"3month","weight":-0.0507},{"period":"6month","weight":0.2128},{"period":"1year","weight":0.0668},{"period":"ytd","weight":0.0455}],"compareEarnings":[{"period":"1week","weight":0.0005},{"period":"1month","weight":0.126},{"period":"3month","weight":0.0253},{"period":"6month","weight":0.0433},{"period":"1year","weight":0.2837},{"period":"ytd","weight":0.0435}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Takeda Pharmaceutical Company Limited是一家在日本注册成立的上市公司成立于1925年1月12日。该公司及其子公司是一家主要的全球制药集团，从事医药产品、非处方药和准药品消费品以及其他医疗保健产品的研究、开发、制造和营销。武田的主要医药产品包括以下治疗领域的药物：胃肠病学、肿瘤学和神经科学。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.042998},{"month":2,"riseRate":0.5,"avgChangeRate":0.004795},{"month":3,"riseRate":0.5,"avgChangeRate":-0.003367},{"month":4,"riseRate":0.5,"avgChangeRate":-0.016765},{"month":5,"riseRate":0.428571,"avgChangeRate":-0.001695},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.012671},{"month":7,"riseRate":0.428571,"avgChangeRate":-0.00545},{"month":8,"riseRate":0.714286,"avgChangeRate":0.014511},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.022057},{"month":10,"riseRate":0.285714,"avgChangeRate":-0.062844},{"month":11,"riseRate":0.714286,"avgChangeRate":0.063577},{"month":12,"riseRate":0.714286,"avgChangeRate":0.019204}],"exchange":"NYSE","name":"武田制药","nameEN":"Takeda Pharmaceutical Co Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.1","shortVersion":"4.42.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"武田制药,TAK,武田制药股票,武田制药股票老虎,武田制药股票老虎国际,武田制药行情,武田制药股票行情,武田制药股价,武田制药股市,武田制药股票价格,武田制药股票交易,武田制药股票购买,武田制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"武田制药(TAK)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供武田制药(TAK)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}